PartnershipAug 4, 2026, 08:53 AM
Akari Discusses WhiteHawk Collaboration, ADC Innovation Strategy
AI Summary
Akari Therapeutics released a CEO Corner segment discussing its strategic research collaboration with WhiteHawk Therapeutics, focusing on combining complementary payload technologies for ADC innovation. CEO Abizer Gaslightwala highlighted the potential of differentiated scientific approaches to accelerate innovation and expand therapeutic opportunities. The company also reiterated its focus on advancing AKTX-101 towards planned Phase 1 clinical evaluation by mid-2027 and expanding its PH1 spliceosome-modulating payload platform.
Key Highlights
- Akari discussed its strategic research collaboration with WhiteHawk Therapeutics in a new CEO Corner segment.
- The collaboration combines Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform.
- The partnership aims to evaluate a novel dual-payload strategy to broaden therapeutic activity.
- Akari is advancing AKTX-101, its lead TROP2-targeting ADC, toward planned Phase 1 clinical evaluation.
- The company aims to start the AKTX-101 First-In-Human trial by mid-2027.
- Akari continues to expand the scientific foundation of its proprietary PH1 spliceosome-modulating payload platform.
- Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5.
Price Impact
More from AKTX